Texas Heart Institute to participate in a study to treat ARDS in hospitalized COVID-19 patients

texas heart institute to participate in a study to treat ards in hospitalized covid 19 patients

Sumary of Texas Heart Institute to participate in a study to treat ARDS in hospitalized COVID-19 patients:

  • As part of the study – which will focus on the sickest of patients – participating ICU patients with ARDS due to COVID-19 will be randomized to receive intravenous infusions of allogeneic mesenchymal stromal cell-based therapy or placebo in addition to maximal care..
  • He added, “My colleagues and I have been working on cell therapy for the heart for the past 20 years, and in that time, we have seen stem cell treatments significantly improve pulmonary function..
  • Related Stories Mesoblast’s remestemcel-L, an intravenous (IV) infusion of allogeneic mesenchymal stem cells (MSCs), has previously been administered in other clinical settings with positive results….

Want to know more click here go to health news source.

From -

Close

Languages